The Weight-loss Effect of GLP-1RAs Glucagon-Like Peptide-1 Receptor Agonists in Non-diabetic Individuals with Overweight or Obesity: A Systematic Review with Meta-Analysis and Trial Sequential Analysis of Randomized Controlled Trials - The American

May 29,2024

GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art - ScienceDirect

Effects on weight loss and glycemic control with SAR441255, a potent unimolecular peptide GLP-1/GIP/GCG receptor triagonist - ScienceDirect

Oral GLP-1 analogue: perspectives and impact on atherosclerosis in type 2 diabetic patients, Cardiovascular Diabetology

Combining glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) in patients with type 2 diabetes mellitus (T2DM), Cardiovascular Diabetology

The relationship between the use of GLP-1 receptor agonists and the incidence of respiratory illness: a meta-analysis of randomized controlled trials, Diabetology & Metabolic Syndrome

Glucagon‐like peptide‐1: Are its roles as endogenous hormone and therapeutic wizard congruent? - Holst - 2022 - Journal of Internal Medicine - Wiley Online Library

Frontiers Basal insulin intensification with GLP-1RA and dual GIP and GLP- 1RA in patients with uncontrolled type 2 diabetes mellitus: A rapid review of randomized controlled trials and meta-analysis

Glucagon-like peptide-1 analogue promotes weight loss in obese, non-diabetic individuals - PACE-CME

Glucagon-like Peptide-1 Receptor Agonists for the Treatment of Type 2 Diabetes in Youth – touchENDOCRINOLOGY

How glucagon-like peptide 1 receptor agonists work in: Endocrine Connections Volume 10 Issue 7 (2021)

Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors

Glucagon-like Peptide-1 (GLP-1) Analogs: Recent Advances, New Possibilities, and Therapeutic Implications

Pharmacotherapy of obesity: an update on the available medications and drugs under investigation - eClinicalMedicine